Dr. Gatti-Mays is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
460 W 10th Ave
Columbus, OH 43210Phone+1 614-293-6529Fax+1 614-293-9469
Summary
- Dr. Margaret Gatti-Mays is an Associate Professor of Medical Oncology at The Ohio State University (Columbus, OH). She is board certified in medical oncology with a primary focus in breast cancer and immuno-oncology. Her research is based in the clinic and focuses on tumor immunology and the development of novel approaches including cancer vaccines, cytokines, antibodies or immune modulators.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2015 - 2017
MedStar Health/Georgetown University HospitalChief Residency, Internal Medicine, 2014 - 2015- MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 2011 - 2014
Georgetown University School of MedicineClass of 2011
Rollins School of Public Health, Emory UniversityMPH, Epidemiology , 2005 - 2007
Certifications & Licensure
OH State Medical License 2020 - 2026
DC State Medical License 2011 - 2020
MD State Medical License 2017 - 2020
VA State Medical License 2013 - 2018- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Fellow ACP, 2019
Clinical Trials
- BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) Start of enrollment: 2021 May 04
- Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer Start of enrollment: 2024 Mar 01
- Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer Start of enrollment: 2019 Nov 12
Publications & Presentations
PubMed
- 168 citationsPhase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumorsMarijo Bilusic, Christopher R. Heery, Julie Collins, Renee N. Donahue, Claudia Palena
Journal for Immunotherapy of Cancer. 2019-09-05 - 231 citationsCurrent Landscape of Immunotherapy in Breast Cancer: A ReviewSylvia Adams, Margaret E. Gatti-Mays, Kevin Kalinsky, Larissa A. Korde, Elad Sharon
JAMA Oncology. 2019-08-01 - 37 citationsA Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild-Type, Advanced Triple-Negative Breast CancerMargaret E. Gatti-Mays, Fatima Karzai, S Soltani, Alexandra S Zimmer, Jeffrey E. Green
The Oncologist. 2020-12-01
Press Mentions
Advances in Breast Cancer: Screening and Treatment Get PersonalOctober 25th, 2024- Breast Cancer Deaths Continue to Decrease as Cases Rise in Younger Adults, Report FindsOctober 16th, 2024
- A Unique Approach for Treating Hormone Receptor Positive Breast CancerApril 21st, 2023
- Join now to see all
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
